NASDAQ: ABEO - Abeona Therapeutics Inc.

Yield per half year: -3.19%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Abeona Therapeutics Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.

more details
The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1980-09-19
ISIN US00289Y2063
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 8.55
Дивиденд ао 3706.25
Сайт https://www.abeonatherapeutics.com
Цена ао 5.63
Change price per day: -2.11% (5.79)
Change price per week: +7.55% (5.27)
Change price per month: +16.87% (4.85)
Change price per 3 month: -5.85% (6.02)
Change price per half year: -3.19% (5.855)
Change price per year: +28.82% (4.4)
Change price per 3 year: +3 400.93% (0.1619)
Change price per 5 year: +139.16% (2.37)
Change price per year to date: +1.76% (5.57)
All parameters

Underestimation

Title Value Grade
P/S 30.36 1
P/BV 7.17 1
P/E 0 0
EV/EBITDA -2.16 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -84.67 0
ROE, % -365.49 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.5 5
Total: 3.78

Debt

Title Value Grade
Debt/EBITDA -0.12 10
Total: 8.8

Growth impulse

Title Value Grade
Yield Revenue, % 16.67 3
Yield Ebitda, % -24.74 0
Yield EPS, % -93.34 0
Total: 0.6
More

Institutions Volume Share, %
Nantahala Capital Management, LLC 4500504 16.45
Adage Capital Partners GP L.L.C. 3249994 11.88
Millennium Management LLC 1418675 5.19
Vanguard Group Inc 1101131 4.03
Western Standard, LLC 808112 2.95
AIGH Capital Management LLC 787769 2.88
Point72 Asset Management, L.P. 760870 2.78
Ikarian Capital, LLC 600000 2.19
Citigroup Inc. 450347 1.65
J. Goldman & Co., L.P. 429816 1.57



Head Job title Payment Year of birth
Dr. Vishwas Seshadri M.B.A., Ph.D. President, CEO & Director 1.49M 1976 (49 years)
Mr. Brian Kevany Ph.D. Senior VP, CTO & CSO N/A
Mr. Gregory Gin Vice President of Investor Relations & Corporate Communications N/A
Ms. Alison Hardgrove Chief People Officer N/A
Mr. Jon Voss VP & Head of Quality N/A 1960 (65 years)
Dr. Madhav Vasanthavada M.B.A., Ph.D. Senior VP, Chief Commercial Officer & Head of Business Development N/A
Mr. Carl Denny Senior Vice President of Regulatory Affairs N/A
Mr. Joseph Walter Vazzano CPA Chief Financial Officer 920.85k 1984 (41 year)
Dr. Brendan M. O'Malley J.D., Ph.D. Senior VP & General Counsel 1970 (55 years)

Address: United States, New York. NY, 1330 Avenue of the Americas - open in Google maps, open in Yandex maps
Website: https://www.abeonatherapeutics.com